Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31

1.

Murine Efficacy and Pharmacokinetic Evaluation of the Flaviviral NS5 Capping Enzyme 2-Thioxothiazolidin-4-One Inhibitor BG-323.

Bullard KM, Gullberg RC, Soltani E, Steel JJ, Geiss BJ, Keenan SM.

PLoS One. 2015 Jun 15;10(6):e0130083. doi: 10.1371/journal.pone.0130083. eCollection 2015.

3.

Malarial kinases: novel targets for in silico approaches to drug discovery.

Bullard KM, DeLisle RK, Keenan SM.

Methods Mol Biol. 2013;993:205-29. doi: 10.1007/978-1-62703-342-8_14. Review.

PMID:
23568473
4.

Identification of a novel antiviral inhibitor of the flavivirus guanylyltransferase enzyme.

Stahla-Beek HJ, April DG, Saeedi BJ, Hannah AM, Keenan SM, Geiss BJ.

J Virol. 2012 Aug;86(16):8730-9. doi: 10.1128/JVI.00384-12. Epub 2012 Jun 6.

5.

A high-throughput screening assay for the identification of flavivirus NS5 capping enzyme GTP-binding inhibitors: implications for antiviral drug development.

Geiss BJ, Stahla-Beek HJ, Hannah AM, Gari HH, Henderson BR, Saeedi BJ, Keenan SM.

J Biomol Screen. 2011 Sep;16(8):852-61. doi: 10.1177/1087057111412183. Epub 2011 Jul 25.

6.

Exploring novel targets for antimalarial drug discovery: plasmodial protein kinases.

Jirage D, Keenan SM, Waters NC.

Infect Disord Drug Targets. 2010 Jun;10(3):134-46. Review.

PMID:
20334624
7.

Focus on flaviviruses: current and future drug targets.

Geiss BJ, Stahla H, Hannah AM, Gari AM, Keenan SM.

Future Med Chem. 2009 May;1(2):327-44. doi: 10.4155/fmc.09.27. Review.

8.

Novel delta opioid receptor agonists exhibit differential stimulation of signaling pathways.

Peng Y, Zhang Q, Arora S, Keenan SM, Kortagere S, Wannemacher KM, Howells RD, Welsh WJ.

Bioorg Med Chem. 2009 Sep 1;17(17):6442-50. doi: 10.1016/j.bmc.2009.07.007. Epub 2009 Jul 9.

PMID:
19646882
9.

Selective inhibition of Pfmrk, a Plasmodium falciparum CDK, by antimalarial 1,3-diaryl-2-propenones.

Geyer JA, Keenan SM, Woodard CL, Thompson PA, Gerena L, Nichols DA, Gutteridge CE, Waters NC.

Bioorg Med Chem Lett. 2009 Apr 1;19(7):1982-5. doi: 10.1016/j.bmcl.2009.02.042. Epub 2009 Feb 13.

PMID:
19250824
10.

Novel microtubule polymerization inhibitor with potent antiproliferative and antitumor activity.

Arora S, Wang XI, Keenan SM, Andaya C, Zhang Q, Peng Y, Welsh WJ.

Cancer Res. 2009 Mar 1;69(5):1910-5. doi: 10.1158/0008-5472.CAN-08-0877. Epub 2009 Feb 17.

11.

Analysis of flavivirus NS5 methyltransferase cap binding.

Geiss BJ, Thompson AA, Andrews AJ, Sons RL, Gari HH, Keenan SM, Peersen OB.

J Mol Biol. 2009 Feb 6;385(5):1643-54. doi: 10.1016/j.jmb.2008.11.058. Epub 2008 Dec 11.

12.

Evaluation of broad spectrum protein kinase inhibitors to probe the architecture of the malarial cyclin dependent protein kinase Pfmrk.

Woodard CL, Keenan SM, Gerena L, Welsh WJ, Geyer JA, Waters NC.

Bioorg Med Chem Lett. 2007 Sep 1;17(17):4961-6. Epub 2007 Jun 12.

PMID:
17588749
13.

Highly potent triazole-based tubulin polymerization inhibitors.

Zhang Q, Peng Y, Wang XI, Keenan SM, Arora S, Welsh WJ.

J Med Chem. 2007 Feb 22;50(4):749-54. Epub 2007 Jan 24.

14.

Discovery of novel triazole-based opioid receptor antagonists.

Zhang Q, Keenan SM, Peng Y, Nair AC, Yu SJ, Howells RD, Welsh WJ.

J Med Chem. 2006 Jul 13;49(14):4044-7.

15.

Structural model of the Plasmodium CDK, Pfmrk, a novel target for malaria therapeutics.

Peng Y, Keenan SM, Welsh WJ.

J Mol Graph Model. 2005 Sep;24(1):72-80.

PMID:
16046158
16.

3D-QSAR comparative molecular field analysis on delta opioid receptor agonist SNC80 and its analogs.

Peng Y, Keenan SM, Zhang Q, Welsh WJ.

J Mol Graph Model. 2005 Sep;24(1):25-33.

PMID:
15950508
17.

Requirement of activated Cdc42-associated kinase for survival of v-Ras-transformed mammalian cells.

Nur-E-Kamal A, Zhang A, Keenan SM, Wang XI, Seraj J, Satoh T, Meiners S, Welsh WJ.

Mol Cancer Res. 2005 May;3(5):297-305.

18.

Elucidation of the Na+, K+-ATPase digitalis binding site.

Keenan SM, DeLisle RK, Welsh WJ, Paula S, Ball WJ Jr.

J Mol Graph Model. 2005 Jun;23(6):465-75.

PMID:
15886034
19.

3D-QSAR comparative molecular field analysis on opioid receptor antagonists: pooling data from different studies.

Peng Y, Keenan SM, Zhang Q, Kholodovych V, Welsh WJ.

J Med Chem. 2005 Mar 10;48(5):1620-9.

PMID:
15743203
20.

Rational inhibitor design and iterative screening in the identification of selective plasmodial cyclin dependent kinase inhibitors.

Keenan SM, Geyer JA, Welsh WJ, Prigge ST, Waters NC.

Comb Chem High Throughput Screen. 2005 Feb;8(1):27-38. Review.

PMID:
15720195
21.
22.
23.

Purification and mass spectrometric analysis of the mu opioid receptor.

Christoffers KH, Li H, Keenan SM, Howells RD.

Brain Res Mol Brain Res. 2003 Oct 21;118(1-2):119-31.

PMID:
14559361
24.

Three-dimensional structure-activity relationship modeling of digoxin inhibition and docking to Na+,K+-ATPase.

Ball WJ Jr, Farr CD, Paula S, Keenan SM, Delisle RK, Welsh WJ.

Ann N Y Acad Sci. 2003 Apr;986:296-7. No abstract available.

PMID:
12763827
25.

Hemodynamic response profile predicts susceptibility to cocaine-induced toxicity.

Williams JB, Keenan SM, Gan Q, Knuepfer MM.

Eur J Pharmacol. 2003 Mar 19;464(2-3):189-96.

PMID:
12620513
26.
27.

Activation and phosphorylation on Thr-160 of nuclear-targeted CDK2 Is ERK dependent.

Lents NH, Keenan SM, Bellone C, Baldassare JJ.

Ann N Y Acad Sci. 2002 Nov;973:265-7. No abstract available.

PMID:
12485874
29.

Stimulation of the Raf/MEK/ERK cascade is necessary and sufficient for activation and Thr-160 phosphorylation of a nuclear-targeted CDK2.

Lents NH, Keenan SM, Bellone C, Baldassare JJ.

J Biol Chem. 2002 Dec 6;277(49):47469-75. Epub 2002 Sep 30.

30.

Molecular scaffold protein and cellular responses.

Keenan SM, Baldassare JJ.

Trends Endocrinol Metab. 2001 Jul;12(5):184-6.

PMID:
11397637
31.

Cyclin-dependent kinase 2 nucleocytoplasmic translocation is regulated by extracellular regulated kinase.

Keenan SM, Bellone C, Baldassare JJ.

J Biol Chem. 2001 Jun 22;276(25):22404-9. Epub 2001 Apr 13.

Supplemental Content

Loading ...
Support Center